News | February 17, 2024
Internal restructuring of foreign subsidiaries at Bliss GVS Pharma
The restructuring aims to create synergies across the business and strengthen capital structure
The restructuring aims to create synergies across the business and strengthen capital structure
The company has reported total income of Rs. 164.63 crores during the period ended June 30, 2023
The company has now received the Establishment Inspection Report (EIR) indicating closure of the inspection
The company has reported total income of Rs. 187.75 crores during the period ended March 31, 2023
The observations are procedural in nature
The company has reported total income of Rs. 211.36 crores during the period ended December 31, 2022
The company had filed a suit in the High Court of Justice, Ghana
The approved product, Mesalamine Suppositories 1000 mg, has an estimated U.S. market size of US$ 29 million
Subscribe To Our Newsletter & Stay Updated
